Frank P. Zemlan
Algemeen Directeur bij Phase 2 Discovery, Inc.
Profiel
Frank P.
Zemlan is Chief Executive Officer of Phase 2 Discovery, Inc. He has over 20 years of experience in clinical research at Merck & Co., Inc., Aventis, Inc., and GlaxoSmithKline Plc.
Dr. Zemlan holds a PhD.
Actieve functies van Frank P. Zemlan
| Bedrijven | Functie | Begin |
|---|---|---|
Phase 2 Discovery, Inc.
 Phase 2 Discovery, Inc. Pharmaceuticals: MajorHealth Technology Phase 2 Discovery, Inc. (P2D) develops central nervous system drugs. The company provides discovery research & development services for pharmaceutical and biotechnology companies. It also develops drugs for treating psychiatric and neurologic disorders. Its products include PD6735, the treatment of primary insomnia and additional indications, N-Substituted Analogs of Benztropine for the treatment of attention deficit hyperactivity disorder & Thiothalidomides and Hydroxythalidomides for the treatment of ALS and MS. Phase 2 Discovery was founded in 1998 and is headquartered in Cincinnati, OH. | Algemeen Directeur | - |
Eerdere bekende functies van Frank P. Zemlan
| Bedrijven | Functie | Einde |
|---|---|---|
| Aventis, Inc. | Corporate Officer/Principal | - |
| GSK PLC | Corporate Officer/Principal | - |
| MERCK & CO., INC. | Corporate Officer/Principal | - |
Opleiding van Frank P. Zemlan
| Villanova University | Graduate Degree |
| University of Pennsylvania | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| GSK PLC | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Phase 2 Discovery, Inc.
Phase 2 Discovery, Inc. Pharmaceuticals: MajorHealth Technology Phase 2 Discovery, Inc. (P2D) develops central nervous system drugs. The company provides discovery research & development services for pharmaceutical and biotechnology companies. It also develops drugs for treating psychiatric and neurologic disorders. Its products include PD6735, the treatment of primary insomnia and additional indications, N-Substituted Analogs of Benztropine for the treatment of attention deficit hyperactivity disorder & Thiothalidomides and Hydroxythalidomides for the treatment of ALS and MS. Phase 2 Discovery was founded in 1998 and is headquartered in Cincinnati, OH. | Health Technology |
| Aventis, Inc. |
